Valuation: Celldex Therapeutics, Inc.

Market Cap 2.27B 2.03B 1.88B 1.71B 3.23B 215B 3.28B 22.64B 8.86B 112B 8.53B 8.34B 359B P/E 2026 *
-6.89x
P/E 2027 * -6.78x
Enterprise Value 1.61B 1.44B 1.34B 1.21B 2.29B 152B 2.33B 16.04B 6.28B 79.54B 6.04B 5.91B 255B EV / Sales 2026 *
870x
EV / Sales 2027 * 165x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celldex Therapeutics, Inc.

1 day+3.93%
1 week-1.26%
Current month-10.74%
1 month-24.88%
3 months-24.48%
6 months-14.59%
Current year+6.52%
1 week 27.65
Extreme 27.65
30.02
1 month 27.65
Extreme 27.65
41.62
Current year 22.33
Extreme 22.33
45.14
1 year 22.1
Extreme 22.1
45.14
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
53.18
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Date Insider Type Main position Quantity % Market Cap. Importance
25/6/26 Free

Executive/Senior Manager

20,000 0.0255%
25/6/26 Free

Director

26,000 0.0331%
25/6/26 Free

Chief Technology Officer

57,000 0.0726%
Change 5-day change 1-year change 3-year change Capi.($)
+3.93%-1.26%+5.82%+10.67% 2.27B
+0.21%-4.63%+55.34%+71.32% 68.98B
+0.29%+4.48%+7.00%+61.91% 53.15B
-0.26%+5.17%+9.78%+41.23% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +1.40%+1.28%+44.12%+89.36% 38.2B
Weighted average by Cap. +1.10%+2.31%+50.42%+102.76%

Financials

2026 *2027 *
Net sales 1.85M 1.65M 1.53M 1.4M 2.63M 175M 2.67M 18.43M 7.21M 91.42M 6.94M 6.8M 293M 9.95M 8.89M 8.26M 7.51M 14.13M 943M 14.39M 99.2M 38.81M 492M 37.36M 36.56M 1.57B
Net income -319M -285M -265M -241M -453M -30.23B -461M -3.18B -1.24B -15.77B -1.2B -1.17B -50.47B -361M -322M -299M -272M -512M -34.19B -522M -3.6B -1.41B -17.84B -1.35B -1.33B -57.08B
Net Debt -662M -591M -549M -500M -940M -62.73B -957M -6.6B -2.58B -32.73B -2.49B -2.43B -105B -633M -565M -526M -478M -899M -60B -916M -6.31B -2.47B -31.3B -2.38B -2.33B -100B
Projected Income Statement - Annual - Celldex Therapeutics, Inc.
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
15/10/26 US$28.93 +3.93% 1,181,696
14/10/26 US$27.84 -1.47% 1,044,322
13/10/26 US$28.25 -4.01% 1,897,949
12/10/26 US$29.43 -1.54% 596,416
09/10/26 US$29.89 +2.01% 992,778
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Celldex Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
28.93USD
Average target price
63.07USD
Spread / Average Target
+118.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Celldex Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CLDX Stock